1. In Vivo

Medtech Innovation And Reinvention Is Part Of The Swiss DNA

Switzerland‘s Medtech And Healthtech Footprint is Growing In All Industrial And Research Areas

 
• By Ashley Yeo

Focus On Switzerland – Part 1: Switzerland is a high-tech microcosm of the medtech industry. It is home to the EMEA headquarters of the world’s largest medtech group, Medtronic, and supports a vibrant SME and start-up community, in the example of hybrid soft tissue robotics company Distalmotion. In Vivo interviewed both for this feature on the contribution of Swiss medtech in the advancement of patient care, domestically and globally.

Bardocz Peter

Swiss medtech is transitioning into the next era of innovation, building on traditional strengths in whole supply chain, discovery, commercial, R&D, production and clinical trials. So says Switzerland Global Enterprise (SGE) director of investment promotion Sirpa Tsimal. “A lot of companies set up a regional headquarters, not just for the Swiss market but also as a hub for Europe or EMEA,” she said.

Medtronic plc is the biggest and probably the most visible example, having moved from Brussels, Belgium to set up...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.